Business Areas

Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.

Sales

Life Science Sales Graph Business Areas LG Chem Life Science Sales Graph Business Areas LG Chem
Sales :2023 ,2024 ,2025
2022 1.2
2023 1.3
2024 1.4

Unit : KRW trillion

Division

Go to the related products ▶

Subsidiary

Go to the related products ▶

VISION

Toward a World-Class Innovative Drug Developer

Life Sciences Vision - Strengthening the Oncology R&D Portfolio: Enhancing the Quality and Efficiency of the New Drug Pipeline, Expanding and Accelerating Global Oncology Clinical Development, Sustaining Investment in New Drug R&D, Global Oncology Pipeline from 6 in 2025 to 10 in 2030. Growing the Global Business: Securing Market Leadership in the U.S. Renal Cancer Therapeutics Market, Diversifying the Global Oncology Product Portfolio, Maximizing Business Potential through Global Partnerships, FOTIVDA(Oncology). Enhancing Market Leadership and Expanding into Overseas Markets: Enhancing the Market Position of Leading Products, Securing next-generation flagship products, Expanding into Asian markets such as Thailand, Eutropin(Growth Hormone), Zemiglo(Diabetes), Follitrope(Fertility), Eupenta(Vaccine)

LG Chem Life Science Pipeline

  • Diabetes & Metabolism
  • Oncology & Immunology
  • Vaccine
  • Aesthetic
  1. Preclinical(2)
    • LR20061 LR20061Atopic Dermatitis
    • LR19157 LR19157Oncology
  2. Phase I(6)
    • LR19129 CUE-102Oncology
    • AV-380 RilogrotugCachexia
    • AV-203 AV-203Oncology
    • LR19155 LB-LR1109Oncology
    • LR19018 LG203003NASH
    • AV-299 FiclatuzumabHematology
  3. Phase II(4)
    • LR20062 aP vaccine
    • LR19021 BivamelagonRare Obesity
    • LR19114 6 in 1 Vaccine
    • LR19019 ZectivimodUlcerative colitis Atopic dermatitis
  4. Phase III(1)
  5. NDA(2)
    • LR20024 Y-solution, MDRHA filler
    • LR19094 Y-solution, ChinaHA filler
Image Download 다운로드

Core Products

Press Releases

LG Chem Achieves First Export Milestone for New Diabetes Combination Drug Zemidapa 2025.05.08
LG Chem Achieves First Export Milestone for New Diabetes Combination Drug Zemidapa 2025.05.08
LG Chem Becomes First Korean Company to Enter Canadian Dermal Filler Market 2024.12.12
more

Video